Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $27.48, for a total transaction of $412,200.00. Following the completion of the transaction, the insider directly owned 460,215 shares of the company’s stock, valued at $12,646,708.20. This represents a 3.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Brian Daniel Webster also recently made the following trade(s):
- On Tuesday, August 4th, Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00.
- On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.92, for a total value of $311,366.64.
- On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.60, for a total value of $202,224.80.
- On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.72, for a total value of $178,511.04.
- On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.81, for a total value of $312,150.00.
Kestra Medical Technologies Stock Down 2.3%
NASDAQ KMTS opened at $27.26 on Friday. The stock’s 50 day moving average is $24.44 and its 200 day moving average is $22.78. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 12 month low of $15.42 and a 12 month high of $30.00. The stock has a market cap of $1.60 billion, a PE ratio of -11.26 and a beta of 0.58.
Analyst Ratings Changes
A number of analysts have issued reports on KMTS shares. Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kestra Medical Technologies has an average rating of “Hold” and an average target price of $28.14.
Get Our Latest Stock Report on KMTS
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at approximately $31,000. Russell Investments Group Ltd. increased its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in Kestra Medical Technologies during the 4th quarter valued at $72,000. BNP Paribas Financial Markets raised its holdings in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the period. Finally, Brown Brothers Harriman & Co. lifted its position in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares during the last quarter.
About Kestra Medical Technologies
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Featured Articles
- Five stocks we like better than Kestra Medical Technologies
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
